Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-07
2011-06-07
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S323000
Reexamination Certificate
active
07956063
ABSTRACT:
The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.
REFERENCES:
patent: 3459731 (1969-08-01), Gramera et al.
patent: 5691364 (1997-11-01), Buckman et al.
patent: 5958935 (1999-09-01), Davis et al.
patent: 6197779 (2001-03-01), Andries et al.
patent: 6838464 (2005-01-01), Pease et al.
patent: 6949544 (2005-09-01), Bethiel et al.
patent: 6982091 (2006-01-01), Pauletti et al.
patent: 7060827 (2006-06-01), Singh et al.
patent: 7125879 (2006-10-01), Guillemont et al.
patent: 7399856 (2008-07-01), Schils et al.
patent: 2006/0034797 (2006-02-01), Arien et al.
patent: 2009/0148531 (2009-06-01), Hantke et al.
patent: 2324919 (1999-10-01), None
patent: 19945982 (1999-09-01), None
patent: 0002341 (1982-01-01), None
patent: 1002795 (1999-05-01), None
patent: 0945443 (1999-09-01), None
patent: 2000-35628 (2000-02-01), None
patent: WO 97/18839 (1997-05-01), None
patent: WO 97/19065 (1997-05-01), None
patent: WO 98/41512 (1998-09-01), None
patent: WO 99/50250 (1999-10-01), None
patent: WO 00/12485 (2000-03-01), None
patent: WO 00/27825 (2000-05-01), None
patent: WO 00/53610 (2000-09-01), None
patent: WO 00/62778 (2000-10-01), None
patent: WO 00/78731 (2000-12-01), None
patent: WO 01/22938 (2001-04-01), None
patent: WO 01/23362 (2001-04-01), None
patent: WO 01/60816 (2001-08-01), None
patent: WO 01/64654 (2001-09-01), None
patent: WO 01/85700 (2001-11-01), None
patent: WO 02/08226 (2002-01-01), None
patent: WO 02/070470 (2002-09-01), None
patent: WO 03/016306 (2003-02-01), None
patent: WO 2004/016581 (2003-02-01), None
patent: WO 2004/050058 (2004-06-01), None
patent: WO 2005/021001 (2005-03-01), None
D'Auria, M., et al., “Photochemical Dimerization in Solution of Arylacrylonitrile Derivatives”, Tetrahedron, vol. 53, No. 51, pp. 17307-17316 (1997).
Denton, et al., “Antiretroviral Pre-Exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice”, PLoS Medicine (Jan. 14, 2008).
Gilead Press Release XP-002314669.
Koyanagi, Y., et al., “Selective Cytotoxicity of Aids Virus Infection Towards HTLV-1-Transformed Cell Lines”, Int. J. Cancer: 36, pp. 445-451 (1985).
Larock, R. C. “Interconversion of Nitriles, Carboxylic Acids and Derivatives”, John Wiley & Sons, Inc. (199) pp. 1983-1985.
Ludovici, D., et al., “Evolution of Anti-HIV Drug Candidates. Part 3: Diarylpyrimidine (DAPY) Analogues”, Bioorganic & Medicinal Chemistry Letters, vol. 11 pp. 2235-2239 (2001).
Mayo Clinic, HIV Infection Symptoms According to Infection Stage, www.mayoclinic.com/health/hiv-aids/DS00005/DSECTION-symptoms (Nov. 2, 2009).
Miles, K., “The Growing HIV Pandemic”, HIV Diagnoses: Community Practitioner (2005) vol. 78, No. 8 pp. 292-294.
Pavia, A., “Abacavir/Lamiviudne in Connection With Efavirenz, Amprenavir/Ritonavir or Stavudine”, XP 002274550. The XIV international AIDS Conference.
Squires, K., “An introduction to Nucleoside and Nucleotide Analogues”, Antiviral Therapy, 6 Suppl.3, XP 009042950 pp. 1-14.
Supuran, CI., et al. “Carbonic Anhyddrase Inhibitors: Synthesis of Sulfonamides Incorporating 2,4,6-Trisubstituted-Pyridinium-Ethylcarboxamido Moieties Possessing Membrane-Impermeability and In Vivo Selectively for the Membrane-Bound (CA IV) Versus the Cytosolic (CA 1 and CA II) Isozymes”. Journal of Enzyme Inhibitor and Medicinal Chemistry vol. 15, pp. 381-340 (2000).
Young, B., “Can Abacavir Be Given Once-A-Day?” the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy XP-002274551.
International Search report, mailing date Nov. 26, 2002, for corresponding Application No. PCT/EP2002/08953.
International Search Report, mailing date Feb. 7, 2005, for corresponding Application No. PCT/EP2004/05028.
Canadian Search Report dated Feb. 19, 2007 for corresponding Application No. CA 2,452,217.
International Preliminary Examination Report dated Dec. 3, 2003 for corresponding Appln. No. PCT/EP2002/08953.
European Search Report dated Dec. 5, 2001 for corresponding Application No. EP 01203090.4.
International Search Report dated Nov. 6, 2003 for related International Application No. PCT/EP2003/50366.
International Preliminary Examination Report dated Nov. 30, 2004 for corresponding Appl. No. PCT/EP03/50366.
Office Action dispatched May 12, 2009 for corresponding Japanese Patent Application No. 521229/03.
Gennaro, AR “Remington Pharmacy”, 19thedition, Medica Panmericana, 1995, pp. 230-235, 245, and, 2226-2234. (in Spanish) English Translation to follow upon receipt.
Gennaro, AR “Remington Pharmacy”, 19thedition, Medica Panmericana, 1995, pp. 230-235, 245, and, 2226-2234. English translation and Certfication attached.(English translation as referenced in the IDS submitted on Dec. 7, 2010.).
Copmans Alex Herman
Guillemont Jérôme Emile Georges
Peeters Jozef
Stappers Alfred Elisabeth
Stevens Paul Theodoor Agnes
Balasubramanian Venkataraman
Janssen Pharmaceutica NV
Shah Rajiv S.
LandOfFree
Salt of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Salt of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Salt of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2703845